Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host pharmacist, Eric Christensen,

and I thank you so much for listening today. As always, go check out real-life pharmacology.com.

Get your free 31-page PDF, top 200 study guide, great little review. For those of you who are practicing in clinical practice

as well as those of you that may be taking board exams or pharmacology exams. So definitely

go snag that for free. We get you updates as to when we've got new podcasts out or potentially

other new content too. So with that, let's get into the drug of the day

today and that is tachrolomus. I have heard it pronounced tachrolomus as well. I prefer it to

chrylamus. The brand name of this medication that I hear most often in clinical practice is Prograph.

And this medication is an immunosuppressive agent. So we're going to suppress the immune system.

So why would we want to do something like that? Well, of course, in organ transplantation,

we don't want our own immune system to potentially attack that transplanted organ. So we

suppress the immune system to try to prevent that from happening.

As far as the classification goes and the mechanism of action,

Tachrolomus is a calcane inhibitor.

Ultimately, this inhibits the activation of T lymphocytes.

And if you remember, T lymphocytes play an important role of adaptive lymphocytes. And if you remember, T lymphocytes play an important role of

adaptive immunity in recognizing new antigens, basically foreign substances that are in the body

and sets up the immune system to help attack that and get rid of that, which under normal

circumstances of infection or, you know, cancerous or malignant cells, that's an appropriate

thing and something that we absolutely want and need to survive. However, in transplantation,

we do not want that immune system, obviously attacking the organ that we're trying to transplant

there. So as you can imagine, there's definitely some challenges with organ transplantation

...